Cargando…

Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors

Immune checkpoint inhibitors (ICIs), represented by anti-CTLA-4 or anti-PD-1/anti-PD-L1 pathway antibodies, have led to a revolution in cancer treatment modalities. ICIs have unique clinical benefits, such as effectiveness against a broad range of tumor types, strong overall impact on survival, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Yingming, Zhao, Fen, Li, Zhenxiang, Yu, Jinming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6086110/
https://www.ncbi.nlm.nih.gov/pubmed/30122997
http://dx.doi.org/10.2147/CMAR.S167400